{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:08:39Z","timestamp":1790348919539,"version":"4.1.0"},"reference-count":146,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.01252","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T05:49:27Z","timestamp":1592459367000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":47,"title":["Anti-dengue Vaccines: From Development to Clinical Trials"],"prefix":"10.3389","volume":"11","author":[{"given":"Josilene Ramos","family":"Pinheiro-Michelsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayane da Silva Oliveira","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itana Vivian Rocha","family":"Santana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia de Souza","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick Carvalho","family":"Mendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson Barros","family":"Luiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime Henrique","family":"Amorim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,6,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1086\/514684","article-title":"Infections due to sandfly fever virus serotype toscana in spain","volume":"27","author":"Mendoza-montero","year":"1998","journal-title":"Clin Infect Dis"},{"key":"B2","first-page":"1101","article-title":"Fields Virology","volume-title":"Flaviviridae: The Viruses and Their Replication","author":"Lindenbach","year":"2007"},{"key":"B3","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S0140-6736(14)60572-9","article-title":"Dengue","volume":"385","author":"Guzman","year":"2015","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.cimid.2004.03.013","article-title":"The changing epidemiology of yellow fever and dengue, 1900 to 2003: full circle?","volume":"27","author":"Gubler","year":"2004","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"7769","DOI":"10.1128\/JVI.75.16.7769-7773.2001","article-title":"Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to vero cells","volume":"75","author":"Crill","year":"2001","journal-title":"J Virol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/nsmb.1382","article-title":"Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins","volume":"15","author":"Lok","year":"2008","journal-title":"Nat Struct Mol Biol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.chom.2010.08.007","article-title":"The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity","volume":"8","author":"Beltramello","year":"2010","journal-title":"Cell Host Microbe"},{"key":"B9","doi-asserted-by":"publisher","first-page":"6631","DOI":"10.1128\/JVI.00316-08","article-title":"Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II","volume":"82","author":"Lai","year":"2008","journal-title":"J Virol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"12149","DOI":"10.1128\/JVI.01732-06","article-title":"Antibody recognition and neutralization determinants on domains I and II of west nile virus envelope protein","volume":"80","author":"Oliphant","year":"2006","journal-title":"J Virol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1093\/infdis\/140.4.527","article-title":"In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody","volume":"140","author":"Halstead","year":"1979","journal-title":"J Infect Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"E378","DOI":"10.1016\/S1473-3099(17)30362-6","article-title":"Personal view achieving safe, effective, and durable zika virus vaccines : lessons from dengue","volume":"17","author":"Halstead","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14760584.2017.1335201","article-title":"A recombinant live attenuated tetravalent vaccine for the prevention of dengue","volume":"16","author":"Guy","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.4269\/ajtmh.13-0304","article-title":"Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil","volume":"89","author":"Dayan","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1097\/INF.0b013e31829b8022","article-title":"Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in latin America","volume":"32","author":"Villar","year":"2013","journal-title":"Pediatr Infect Dis J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"724","DOI":"10.4269\/ajtmh.2011.10-0436","article-title":"Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans","volume":"85","author":"Qiao","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"B17","doi-asserted-by":"publisher","first-page":"5935","DOI":"10.1016\/j.vaccine.2012.07.043","article-title":"Immunogenicity and safety of tetravalent dengue vaccine in 2 - 11 year-olds previously vaccinated against yellow fever : randomized, controlled, phase II study in Piura, Peru","volume":"30","author":"Lanata","year":"2012","journal-title":"Vaccine"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.4161\/hv.21224","article-title":"Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2 - 45 years Phase II randomized controlled trial in Singapore","volume":"8","author":"Leo","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"B19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4172\/2157-7560.1000162","article-title":"Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (CYD- TDV) in healthy vietnamese adults and children","volume":"3","author":"Tran","year":"2012","journal-title":"J Vaccine Vaccin"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-018-3389-x","article-title":"Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults","volume":"18","author":"Kirstein","year":"2018","journal-title":"BMC Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial","volume":"380","author":"Sabchareon","year":"2012","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"ofv172","DOI":"10.1093\/ofid\/ofv172","article-title":"Influence of Fc\u03b3riia-expressing cells on the assessment of neutralizing and enhancing serum antibodies elicited by a live-attenuated tetravalent dengue vaccine","volume":"2","author":"Byers","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1097\/INF.0000000000001250","article-title":"Immunogenicity and safety of yellow fever vaccine (Stamaril) when administered concomitantly with a tetravalent dengue vaccine candidate in healthy toddlers at 12-13 months of age in Colombia and Peru a randomized trial","volume":"35","author":"Lopez","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"B26","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.4161\/hv.25562","article-title":"Persistence of Th1\/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore","volume":"9","author":"Harenberg","year":"2013","journal-title":"Hum Vaccines Immunother"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1016\/j.vaccine.2016.04.028","article-title":"Detection of dengue cases by serological testing in a dengue vaccine efficacy trial: utility for efficacy evaluation and impact of future vaccine introduction","volume":"34","author":"Plennevaux","year":"2016","journal-title":"Vaccine"},{"key":"B29","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1080\/21645515.2015.1076598","article-title":"Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: a randomized, observer-blind, placebo-controlled phase II trial","volume":"12","author":"Dubey","year":"2016","journal-title":"Hum Vaccines Immunother."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.4161\/21645515.2014.972131","article-title":"Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naive adults in Mexico","volume":"10","author":"Dayan","year":"2014","journal-title":"Hum Vaccines Immunother"},{"key":"B31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.cmi.2018.01.018","article-title":"Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America","volume":"24","author":"Arredondo-Garc\u00eda","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1056\/NEJMoa1503877","article-title":"Symptomatic dengue in children in 10 Asian and Latin American countries","volume":"374","author":"L'Azou","year":"2016","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1093\/cid\/cix966","article-title":"Impact of dengue vaccination on serological diagnosis: insights from phase III dengue vaccine efficacy trials","volume":"66","author":"Plennevaux","year":"2018","journal-title":"Clin Infect Dis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e24196","DOI":"10.7554\/eLife.24196.056","article-title":"Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy","volume":"6","author":"Rabaa","year":"2017","journal-title":"Elife"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e0004830","DOI":"10.1371\/journal.pntd.0004830","article-title":"Cytokine profile of children hospitalized with virologically-confirmed dengue during two phase III vaccine efficacy trials","volume":"10","author":"Harenberg","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"B37","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1093\/infdis\/jiw297","article-title":"Tetravalent dengue vaccine reduces symptomatic and asymptomatic dengue virus infections in healthy children and adolescents aged 2-16 years in Asia and Latin America","volume":"214","author":"Olivera-Botello","year":"2016","journal-title":"J Infect Dis"},{"key":"B38","doi-asserted-by":"publisher","first-page":"6417","DOI":"10.1016\/j.vaccine.2015.11.023","article-title":"Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies","volume":"34","author":"Coudeville","year":"2016","journal-title":"Vaccine"},{"key":"B39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nrmicro.2015.2","article-title":"Dengue vaccine: hypotheses to understand CYD-TDV-induced protection","volume":"14","author":"Guy","year":"2015","journal-title":"Nat Rev Microbiol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e0004821","DOI":"10.1371\/journal.pntd.0004821","article-title":"Safety overview of a recombinant live-attenuated tetravalent dengue vaccine: pooled analysis of data from 18 clinical trials","volume":"10","author":"Gailhardou","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1080\/21645515.2017.1333211","article-title":"Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination","volume":"13","author":"Vigne","year":"2017","journal-title":"Hum Vaccines Immunother."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e0004918","DOI":"10.1371\/journal.pntd.0004918","article-title":"Symptomatic dengue disease in five southeast asian countries: epidemiological evidence from a dengue vaccine trial","volume":"10","author":"Nealon","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"B43","doi-asserted-by":"publisher","first-page":"6426","DOI":"10.1016\/j.vaccine.2016.08.050","article-title":"Potential impact of dengue vaccination: insights from two large-scale phase III trials with a tetravalent dengue vaccine","volume":"34","author":"Coudeville","year":"2016","journal-title":"Vaccine"},{"key":"B44","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1097\/INF.0000000000001542","article-title":"Immunogenicity and safety of a booster injection of DTap-IPV\/\/Hib (Pentaxim) administered concomitantly with tetravalent dengue vaccine in healthy toddlers 15-18 months of age in Mexico: a randomized trial","volume":"36","author":"Melo","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"B45","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/infdis\/jix314","article-title":"Replication and excretion of the live attenuated tetravalent dengue vaccine CYD-TDV in a flavivirus-naive adult population: assessment of vaccine viremia and virus shedding","volume":"216","author":"Torresi","year":"2017","journal-title":"J Infect Dis"},{"key":"B46","doi-asserted-by":"publisher","first-page":"5127","DOI":"10.1016\/j.vaccine.2015.08.008","article-title":"Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study","volume":"33","author":"Torresi","year":"2015","journal-title":"Vaccine"},{"key":"B47","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1093\/infdis\/jiw576","article-title":"Dissecting antibodies induced by a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in na\u00efve and dengue exposed individuals","volume":"215","author":"Henein","year":"2016","journal-title":"J Infect Dis"},{"key":"B48","doi-asserted-by":"publisher","first-page":"5814","DOI":"10.1016\/j.vaccine.2013.10.013","article-title":"Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2 - 11 years in Malaysia : a randomized, placebo-controlled, phase III study","volume":"31","author":"Hss","year":"2013","journal-title":"Vaccine"},{"key":"B49","doi-asserted-by":"publisher","first-page":"255","DOI":"10.4161\/hv.2.6.3494","article-title":"rDEN2\/4\u039430(ME), a live attenuated chimeric dengue serotype 2 vaccine, is safe and highly immunogenic in healthy dengue-na\u00efve adults","volume":"2","author":"Durbin","year":"2006","journal-title":"Hum Vaccin"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1093\/infdis\/jiy434","article-title":"Early transcriptional responses after dengue vaccination mirror the response to natural infection and predict neutralizing antibody titers","volume":"218","author":"Popper","year":"2018","journal-title":"J Infect Dis"},{"key":"B51","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1093\/infdis\/jiw067","article-title":"A 12-month-interval dosing study in adults indicates that a single dose of the national institute of allergy and infectious diseases tetravalent dengue vaccine induces a robust neutralizing antibody response","volume":"214","author":"Durbin","year":"2016","journal-title":"J Infect Dis"},{"key":"B52","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1093\/infdis\/jiv082","article-title":"Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults","volume":"212","author":"Kirkpatrick","year":"2015","journal-title":"J Infect Dis"},{"key":"B53","doi-asserted-by":"publisher","first-page":"330ra36","DOI":"10.1126\/scitranslmed.aaf1517","article-title":"The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model","volume":"8","author":"Kirkpatrick","year":"2016","journal-title":"Sci Transl Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"7075","DOI":"10.1016\/j.vaccine.2015.09.052","article-title":"Dengue human infection models to advance dengue vaccine development","volume":"33","author":"Larsen","year":"2015","journal-title":"Vaccine"},{"key":"B55","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S0264-410X(00)00040-2","article-title":"Live attenuated tetravalent dengue vaccine","volume":"18","author":"Bhamarapravati","year":"2000","journal-title":"Vaccine"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1093\/infdis\/jiv179","article-title":"Safety and immunogenicity of a live attenuated tetravalent dengue vaccine candidate in flavivirus-naive adults: a randomized, double-blinded phase 1 clinical trial","volume":"212","author":"George","year":"2015","journal-title":"J Infect Dis"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e0005584","DOI":"10.1371\/journal.pntd.0005584","article-title":"In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well- tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination","volume":"11","author":"Whitehead","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1126\/science.aac5017","article-title":"HHS public access","volume":"349","author":"Katzelnick","year":"2016","journal-title":"J Immigr Minor Health"},{"key":"B59","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/infdis\/jiq059","article-title":"Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines : implications for vaccination of populations in areas where dengue is endemic","volume":"203","author":"Durbin","year":"2011","journal-title":"J Infect Dis"},{"key":"B60","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S1473-3099(14)70811-4","article-title":"Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study","volume":"14","author":"Osorio","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"B61","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1473-3099(17)30632-1","article-title":"Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study","volume":"18","author":"S\u00e1ez-Llorens","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"B62","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S1473-3099(17)30166-4","article-title":"Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study","volume":"17","author":"S\u00e1ez-Llorens","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"B63","doi-asserted-by":"publisher","first-page":"3976","DOI":"10.1016\/j.vaccine.2018.05.028","article-title":"A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate","volume":"36","author":"Jackson","year":"2018","journal-title":"Vaccine"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1093\/infdis\/jiy063","article-title":"Analyzing the human serum antibody responses to a live attenuated tetravalent dengue vaccine candidate","volume":"217","author":"Swanstrom","year":"2018","journal-title":"J Infect Dis"},{"key":"B65","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4269\/ajtmh.2012.12-0361","article-title":"A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults","volume":"88","author":"Thomas","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"B66","doi-asserted-by":"publisher","first-page":"441","DOI":"10.4269\/ajtmh.14-0625","article-title":"A phase II, randomized, safety and immunogenicity trial of a re-derived, live-attenuated dengue virus vaccine in healthy children and adults living in puerto rico","volume":"93","author":"Bauer","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"B67","doi-asserted-by":"publisher","first-page":"426","DOI":"10.4269\/ajtmh.2008.78.426","article-title":"Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children","volume":"78","author":"Simasathien","year":"2008","journal-title":"Am J Trop Med Hyg"},{"key":"B68","doi-asserted-by":"publisher","first-page":"341","DOI":"10.4269\/ajtmh.2011.10-0501","article-title":"Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants","volume":"85","author":"Thomas","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.4269\/ajtmh.16-0634","article-title":"Phase 1 randomized study of a tetravalent dengue purified inactivated vaccine in healthy adults in the United States","volume":"96","author":"Schmidt","year":"2017","journal-title":"Am J Trop Med Hyg"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.4269\/ajtmh.17-0627","article-title":"Phase I randomized study of a tetravalent dengue purified inactivated vaccine in healthy adults from puerto rico","volume":"98","author":"Diaz","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"B71","doi-asserted-by":"publisher","first-page":"849","DOI":"10.4269\/ajtmh.17-0416","article-title":"Safety and immunogenicity of a tetravalent dengue DNA vaccine administered with a cationic lipid-based adjuvant in a phase 1 clinical trial","volume":"98","author":"Danko","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"B72","doi-asserted-by":"publisher","first-page":"7126","DOI":"10.1016\/j.vaccine.2015.09.101","article-title":"Preclinical and clinical development of a dengue recombinant subunit vaccine","volume":"33","author":"Manoff","year":"2015","journal-title":"Vaccine"},{"key":"B73","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1080\/21645515.2018.1546523","article-title":"Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-Na\u00efve adults","volume":"15","author":"Manoff","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"B74","doi-asserted-by":"publisher","first-page":"10342","DOI":"10.1073\/pnas.88.22.10342","article-title":"Construction of intertypic chimeric dengue viruses by substitution of structural protein genes","volume":"88","author":"Bray","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"B75","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1128\/JVI.73.4.3095-3101.1999","article-title":"Yellow fever\/Japanese encephalitis chimeric viruses: construction and biological properties","volume":"73","author":"Chambers","year":"1999","journal-title":"J Virol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"4761","DOI":"10.1128\/JVI.78.9.4761-4775.2004","article-title":"Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates","volume":"78","author":"Guirakhoo","year":"2004","journal-title":"J Virol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.1128\/JVI.74.12.5477-5485.2000","article-title":"Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates","volume":"74","author":"Guirakhoo","year":"2000","journal-title":"J Virol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"7290","DOI":"10.1128\/JVI.75.16.7290-7304.2001","article-title":"Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine","volume":"75","author":"Guirakhoo","year":"2001","journal-title":"J Virol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1099\/0022-1317-69-6-1391","article-title":"Partial nucleotide sequence and deduced amino acid sequence of the structural proteins of dengue virus type 2, new Guinea C and PUO-218 strains","volume":"69","author":"Gruenberg","year":"1988","journal-title":"J Gen Virol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"74","DOI":"10.4269\/ajtmh.2005.72.74","article-title":"Replication of chimeric yellow fever virus \u2013 dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells","volume":"72","author":"Brandler","year":"2005","journal-title":"Am J Drop Med Hyg"},{"key":"B81","doi-asserted-by":"publisher","first-page":"986","DOI":"10.4269\/ajtmh.2006.75.986","article-title":"Growth characteristics of chimerivax-den vaccine viruses in aedes aegypti and aedes albopictus from Thailand","volume":"75","author":"Higgs","year":"2006","journal-title":"Am J Drop Med Hyg"},{"key":"B82","doi-asserted-by":"publisher","first-page":"60","DOI":"10.4161\/hv.2.2.2555","article-title":"Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax TM - ND SC RIB","volume":"2","author":"Guirakhoo","year":"2006","journal-title":"Hum Vaccine"},{"key":"B83","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1097\/INF.0b013e3181fe05af","article-title":"Live-attenuated tetravalent dengue vaccine in dengue-na\u00efve children, adolescents, and adults in Mexico city","volume":"30","author":"Poo","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"B84","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1086\/649916","article-title":"A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus -naive adults","volume":"201","author":"Morrison","year":"2010","journal-title":"J Infect Dis"},{"key":"B85","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1016\/j.vaccine.2011.03.057","article-title":"Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the philippines","volume":"29","author":"Capeding","year":"2011","journal-title":"Vaccine"},{"key":"B86","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1016\/S1473-3099(18)30494-8","article-title":"Personal view deliberations of the strategic advisory group of experts on immunization on the use of CYD-TDV dengue vaccine","volume":"19","author":"Wilder-smith","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"B87","doi-asserted-by":"publisher","first-page":"5712","DOI":"10.1016\/j.vaccine.2008.08.019","article-title":"Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects","volume":"26","author":"Guy","year":"2008","journal-title":"Vaccine"},{"key":"B88","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2217\/cer-2016-0045","article-title":"CYD-TDV dengue vaccine: systematic review and meta-analysis of efficacy, immunogenicity and safety","volume":"6","author":"God\u00f3i","year":"2017","journal-title":"J Comp Eff Res"},{"key":"B89","doi-asserted-by":"publisher","first-page":"3930","DOI":"10.1128\/JVI.70.6.3930-3937.1996","article-title":"Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys","volume":"70","author":"Men","year":"1996","journal-title":"J Virol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"414","DOI":"10.4269\/ajtmh.2001.65.414","article-title":"A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes","volume":"65","author":"Troyer","year":"2001","journal-title":"Am J Trop Med Hyg"},{"key":"B91","doi-asserted-by":"publisher","first-page":"405","DOI":"10.4269\/ajtmh.2001.65.405","article-title":"Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region","volume":"65","author":"Durbin","year":"2001","journal-title":"Am J Trop Med Hyg"},{"key":"B92","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1086\/427780","article-title":"rDEN4\u039430, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers","volume":"191","author":"Durbin","year":"2005","journal-title":"J Infect Dis"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1128\/JVI.77.2.1653-1657.2003","article-title":"A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3' untranslated region is highly attenuated and immunogenic in monkeys","volume":"77","author":"Whitehead","year":"2003","journal-title":"J Virol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"24","DOI":"10.4269\/ajtmh.2003.69.6_suppl.0690024","article-title":"Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates","volume":"69","author":"Sun","year":"2003","journal-title":"Am J Trop Med Hyg"},{"key":"B95","doi-asserted-by":"publisher","first-page":"167","DOI":"10.4161\/hv.2.4.2944","article-title":"The live attenuated dengue serotype 1 vaccine rDEN1\u039430 is safe and highly immunogenic in healthy adult volunteers","volume":"2","author":"Durbin","year":"2006","journal-title":"Hum Vaccin"},{"key":"B96","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1089\/vim.2006.19.10","article-title":"Development of a live attenuated dengue virus vaccine using reverse genetics","volume":"19","author":"Blaney","year":"2006","journal-title":"Viral Immunol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"4307","DOI":"10.1016\/S0264-410X(03)00488-2","article-title":"Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys","volume":"21","author":"Whitehead","year":"2003","journal-title":"Vaccine"},{"key":"B98","doi-asserted-by":"publisher","first-page":"811","DOI":"10.4269\/ajtmh.2004.71.811","article-title":"Genetically modified, live attenuated dengue virus type 3 vaccine candidates","volume":"71","author":"Blaney","year":"2004","journal-title":"Am J Trop Med Hyg"},{"key":"B99","doi-asserted-by":"publisher","first-page":"7242","DOI":"10.1016\/j.vaccine.2011.07.023","article-title":"Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine","volume":"29","author":"Durbin","year":"2011","journal-title":"Vaccine"},{"key":"B100","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.vaccine.2007.11.082","article-title":"Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3\u2032 untranslated region (3\u2032-UTR) or by exchange of the DENV-3 3\u2032-UTR with that of DENV-4","volume":"26","author":"Blaney","year":"2008","journal-title":"Vaccine"},{"key":"B101","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1016\/j.vaccine.2013.05.075","article-title":"Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles","volume":"31","author":"Lindow","year":"2013","journal-title":"Vaccine"},{"key":"B102","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1093\/infdis\/jis936","article-title":"A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial","volume":"207","author":"Durbin","year":"2013","journal-title":"J Infect Dis"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2334-4-39","article-title":"Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2","volume":"4","author":"Blaney","year":"2004","journal-title":"BMC Infect Dis"},{"key":"B104","doi-asserted-by":"publisher","first-page":"6351","DOI":"10.1016\/j.vaccine.2015.09.008","article-title":"Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: a Phase 1b randomized study","volume":"33","author":"Rupp","year":"2015","journal-title":"Vaccine"},{"key":"B105","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1128\/JVI.74.7.3011-3019.2000","article-title":"Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3","volume":"74","author":"Butrapet","year":"2000","journal-title":"J Virol"},{"key":"B106","first-page":"189","article-title":"Immunization with a live attenuated dengue-2-virus logical and biological responses in adult volunteers","volume":"65","author":"Bhamarapravati","year":"1987","journal-title":"Bull World Health Organ"},{"key":"B107","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1006\/viro.1997.8500","article-title":"Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53","volume":"230","author":"Kinney","year":"1997","journal-title":"Virology"},{"key":"B108","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1089\/vbz.2010.0150","article-title":"Replication of the primary dog kidney-53 dengue 2 virus vaccine candidate in aedes aegypti is modulated by a mutation in the 5\u2032 untranslated region and amino acid substitutions in nonstructural proteins 1 and 3","volume":"11","author":"Butrapet","year":"2000","journal-title":"Vector Borne Zoonotic Dis"},{"key":"B109","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4269\/ajtmh.2003.69.6_suppl.0690005","article-title":"Biologic properties of dengue viruses following serial passage in primary dog kidney cells: studies at the university of Hawaii","volume":"69","author":"Halstead","year":"2003","journal-title":"Am J Trop Med Hyg"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.vaccine.2005.09.029","article-title":"Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults","volume":"24","author":"Kitchener","year":"2006","journal-title":"Vaccine"},{"key":"B111","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/0264-410X(95)00167-Y","article-title":"Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers","volume":"14","author":"Vaughn","year":"1996","journal-title":"Vaccine"},{"key":"B112","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1128\/JVI.74.7.3020-3028.2000","article-title":"Chimeric dengue type 2 (vaccine strain PDK-53)\/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine","volume":"74","author":"Huang","year":"2000","journal-title":"J Virol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"11436","DOI":"10.1128\/JVI.77.21.11436-11447.2003","article-title":"Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development","volume":"77","author":"Huang","year":"2003","journal-title":"J Virol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"e2243","DOI":"10.1371\/journal.pntd.0002243","article-title":"Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax)","volume":"7","author":"Huang","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"B115","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1586\/14760584.2016.1128328","article-title":"A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone","volume":"15","author":"Osorio","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.vaccine.2011.11.072","article-title":"Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice","volume":"30","author":"Brewoo","year":"2012","journal-title":"Vaccine"},{"key":"B117","doi-asserted-by":"publisher","first-page":"978","DOI":"10.4269\/ajtmh.2011.10-0592","article-title":"Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in cynomolgus macaques","volume":"84","author":"Osorio","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"B118","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children and adolescents","volume":"381","author":"Biswal","year":"2019","journal-title":"N Engl J Med"},{"key":"B119","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4269\/ajtmh.2003.69.12","article-title":"Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys","volume":"69","author":"Eckels","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"B120","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4269\/ajtmh.2003.69.48","article-title":"Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine","volume":"69","author":"Edelman","year":"2003","journal-title":"Am J Trop Med Hyg"},{"key":"B121","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4161\/hv.5.1.6348","article-title":"Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-na\u00efve adults","volume":"5","author":"Sun","year":"2009","journal-title":"Hum Vaccin"},{"key":"B122","doi-asserted-by":"publisher","first-page":"119","DOI":"10.4269\/ajtmh.13-0452","article-title":"Safety and immunogenicity of a rederived, live-attenuated dengue virus vaccine in healthy adults living in Thailand: a randomized trial","volume":"91","author":"Tournay","year":"2014","journal-title":"Am J Trop Med Hyg"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1093\/infdis\/174.6.1176","article-title":"Development of a purified, inactivated, dengue-2 virus vaccine prototype in vero cells: immunogenicity and protection in mice and rhesus monkeys","volume":"174","author":"Putnak","year":"1996","journal-title":"J Infect Dis"},{"key":"B124","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.1016\/j.vaccine.2005.03.042","article-title":"An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model","volume":"23","author":"Robert Putnak","year":"2005","journal-title":"Vaccine"},{"key":"B125","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.virol.2009.10.023","article-title":"Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy","volume":"396","author":"Simmons","year":"2010","journal-title":"Virology"},{"key":"B126","doi-asserted-by":"publisher","first-page":"698","DOI":"10.4269\/ajtmh.14-0268","article-title":"An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques","volume":"92","author":"Fernandez","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"B127","doi-asserted-by":"publisher","first-page":"454","DOI":"10.4269\/ajtmh.14-0819","article-title":"Safety and immunogenicity of a dengue virus serotype-1 purified-inactivated vaccine: results of a phase 1 clinical trial","volume":"93","author":"Martinez","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"B128","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","article-title":"Adjuvant system AS01: helping to overcome the challenges of modern vaccines","volume":"16","author":"Didierlaurent","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"B129","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1586\/erv.11.29","article-title":"Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems","volume":"10","author":"Gar\u00e7on","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"B130","doi-asserted-by":"publisher","first-page":"e1007721","DOI":"10.1371\/journal.ppat.1007721","article-title":"Detection of post-vaccination enhanced dengue virus infection in macaques : an improved model for early assessment of dengue vaccines","volume":"15","author":"Borges","year":"2019","journal-title":"PLoS Pathog"},{"key":"B131","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.vaccine.2011.10.085","article-title":"Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine","volume":"30","author":"Porter","year":"2012","journal-title":"Vaccine"},{"key":"B132","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.4161\/hv.21806","article-title":"A dengue DNA vaccine formulated with Vaxfectin\u00ae is well tolerated, and elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits","volume":"8","author":"Raviprakash","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"B133","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1016\/S0264-410X(99)00570-8","article-title":"Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein","volume":"18","author":"Raviprakash","year":"2000","journal-title":"Vaccine"},{"key":"B134","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0264-410X(97)00215-6","article-title":"Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice","volume":"15","author":"Kochel","year":"1997","journal-title":"Vaccine"},{"key":"B135","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s007050050348","article-title":"Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses","volume":"143","author":"Porter","year":"1998","journal-title":"Arch Virol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1016\/S0264-410X(03)00009-4","article-title":"Dengue 2 PreM-E\/LAMP chimera targeted to the MHC class II compartment elicits long-lasting neutralizing antibodies","volume":"21","author":"Lu","year":"2003","journal-title":"Vaccine"},{"key":"B137","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.vaccine.2005.09.032","article-title":"Evaluation of immunity and protective efficacy of a dengue-3 pre-membrane and envelope DNA vaccine in Aotus nancymae monkeys","volume":"24","author":"Blair","year":"2006","journal-title":"Vaccine"},{"key":"B138","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.virol.2006.05.005","article-title":"A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques","volume":"353","author":"Raviprakash","year":"2006","journal-title":"Virology"},{"key":"B139","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1016\/j.vaccine.2010.01.022","article-title":"Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys","volume":"28","author":"Clements","year":"2010","journal-title":"Vaccine"},{"key":"B140","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1128\/IAI.14.5.1221-1227.1976","article-title":"Isolation of a temperature-sensitive dengue-2 virus under conditions suitable for vaccine development","volume":"14","author":"Eckels","year":"1976","journal-title":"Infect Immun"},{"key":"B141","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0042-6822(88)90406-0","article-title":"Nucleotide sequence of dengue 2 RNA and comparison of the encoded proteins with those of other flaviviruses","volume":"162","author":"Hahn","year":"1988","journal-title":"Virology"},{"key":"B142","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/BF00569739","article-title":"Nucleotide sequence of dengue type 3 virus genomic RNA encoding viral structural proteins","volume":"2","author":"Osatomi","year":"1988","journal-title":"Virus Genes"},{"key":"B143","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0042-6822(86)90169-8","article-title":"Cloning full-length dengue type 4 viral DNA sequences: analysis of genes coding for structural proteins","volume":"155","author":"Zhao","year":"1986","journal-title":"Virology"},{"key":"B144","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1016\/j.vaccine.2015.06.067","article-title":"Preclinical development of a dengue tetravalent recombinant subunit vaccine: immunogenicity and protective efficacy in nonhuman primates","volume":"33","author":"Govindarajan","year":"2015","journal-title":"Vaccine"},{"key":"B145","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.3389\/fimmu.2019.02260","article-title":"Seeking flavivirus cross-protective immunity","volume":"10","author":"Dos Santos Franco","year":"2019","journal-title":"Front Immunol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1128\/JVI.02129-14","article-title":"The human CD8 + T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes","volume":"89","author":"Weiskopf","year":"2015","journal-title":"J Virol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01252\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T05:49:30Z","timestamp":1592459370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01252\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,18]]},"references-count":146,"alternative-id":["10.3389\/fimmu.2020.01252"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.01252","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,18]]},"article-number":"1252"}}